Live: Tuesday 31st January 2023 | 16:00 UTC
Join this live 60-minute webinar with our expert faculty as they discuss early and optimal management of adrenocortical carcinoma (ACC). Watch as our experts in ACC present real-life patient scenarios, and discuss how best to approach and manage these specific cases. Then take the opportunity to have your questions answered by the experts themselves in two separate Q&A sessions (agenda).
|Time||Early and optimal management of adrenocortical carcinoma (ACC)
Tuesday 31st January 2023 | 16:00–17:00 UTC/17:00–18:00 CET
|UTC||CET||Chair: Professor Alfredo Berruti|
|16:00 - 16:05||17:00 - 17:05||Welcome and introductions||Professor Alfredo Berruti|
|16:05 - 16:30||17:00 - 17:30||Session 1: Treatment algorithms in ACC – a patient case study, followed by Q&A||Professor Alfredo Berruti|
|16:30 - 16:55||17:30 - 17:55||Session 2: Treatment combination side effects – a patient case study, followed by Q&A||Professor Jaydira Del Rivero|
|16:55 - 17:00||17:55 - 18:00||Closing remarks||All faculty|
Don’t miss this opportunity to gain expert perspective on a complex and evolving topic
Adrenocortical carcinoma (ACC) is a rare and aggressive cancer. Given its rarity, there is a need to raise awareness of ACC, including current recommendations and strategies for management. In this live webinar, experts in ACC will discuss and highlight important clinical considerations such as treatment choice, management of complex patient cases and variations in guideline recommendations.
Professor Alfredo Berruti
Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Spedali Civili Hospital, Brescia, Italy.
Professor Alfredo Berruti is a full Professor of Medical Oncology at the University of Brescia, Director of the Oncology Unit and of the Oncology Department of the Spediali Civili Hospital in Brescia, Director of the School of Specialization in Oncology of the University of Brescia and Dean of Degree Course in Medicine and Surgery at University of Brescia.
Professor Jaydira Del Rivero
Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, United States; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, United States.
Professor Del Rivero earned her medical degree from the University of Veracruz in Veracruz, Mexico and completed her internal medicine residency at Woodhull Medical and Mental Health Center/NYU-Langone Medical Center. Professor Del Rivero is the Principal Investigator of the Natural History Study for Neuroendocrine Neoplasm and Adrenocortical Cancer to provide the basis of further development of therapeutic interventions, prevention/screening guidelines, endpoints for future clinical trials. Professsor Del Rivero’s current efforts are the development of novel treatment approaches and targeted therapies for endocrine malignancies such as advanced gastroenteropancreatic neuroendocrine tumors, adrenocortical cancer and pheochromocytoma/paraganglioma.
This content has been developed independently of the sponsor, HRA Pharma Rare Diseases, which has had no editorial input into the content. Medthority received educational funding from the sponsor in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content.